Welcome to our dedicated page for GLOBUS MEDICAL SEC filings (Ticker: GMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Globus Medical filings document formal disclosures for a medical device company focused on musculoskeletal solutions and enabling technologies. Recent Form 8-K reports furnish quarterly and annual operating results, preliminary sales information, financial guidance and related press releases covering net sales, earnings measures, cash flow and segment commentary.
The company’s proxy materials cover board elections, governance practices, executive compensation, equity awards and annual meeting matters. Other current reports document leadership transitions, director departures and related governance events, tying the filing record to Globus Medical’s operating performance, management structure and public-company reporting obligations.
Globus Medical Inc. filed an insider trading report showing a new stock option grant to director Stephen T. Zarrilli. On January 21, 2026, he received options to buy 15,000 shares of Class A common stock at an exercise price of $94.15 per share. The grant was recorded at a price of $0 because it reflects an award, not a purchase in the market. These options are held directly and will vest on January 1, 2027, with an expiration date of January 21, 2036.
Globus Medical Inc. director John A. DeFord reported a grant of stock options linked to the company’s Class A common stock. On January 21, 2026, he received 15,000 stock options with an exercise price of $94.15 per share and no cost at grant. According to the disclosure, these options will vest on January 1, 2027, and DeFord now beneficially owns 15,000 derivative securities directly following this transaction.
Globus Medical Inc. granted stock options to director Dan Wolterman. On January 21, 2026, he received options to buy 15,000 shares of Class A common stock at an exercise price of $94.15 per share. These options were granted at no cost to him and are held as a direct ownership position.
The options will vest on January 1, 2027, meaning they become exercisable on that date and remain outstanding until their expiration on January 21, 2036. Following this grant, Wolterman beneficially owns 15,000 derivative securities in the form of these stock options.
Globus Medical Inc. director David D. Davidar received a stock option grant for 15,000 derivative securities tied to Class A common stock. The options were granted on January 21, 2026 at a conversion or exercise price of $94.15 per share and had no purchase price for the derivative security itself. Following this grant, 15,000 derivative securities are beneficially owned on a direct basis.
The options will vest on January 1, 2027 and are scheduled to expire on January 21, 2036. Each option represents the right to buy one share of Class A common stock, so the grant covers 15,000 underlying shares.
Globus Medical Inc. reported that executive Kelly G. Huller, EVP, General Counsel and Corporate Secretary, received a grant of stock options on January 21, 2026. The award covers 40,000 stock options to buy Class A common stock at an exercise price of $94.15 per share, with the options held directly.
According to the vesting terms, the options vest over four years, with 25% vesting on January 1, 2027, and the remaining options vesting in equal monthly installments of 1/48 each month thereafter. The options have an expiration date of January 21, 2036, giving the executive a long-term incentive tied to the company’s share performance.
Globus Medical Inc. senior vice president and CFO filed an amended insider trading report updating details of a prior stock option exercise and share sale. The amendment clarifies that on December 1, 2025, the officer exercised 4,896 stock options with an exercise price of $63.68 and then sold the underlying 4,896 shares of Class A common stock, rather than 5,000 options as previously reported.
The options relate to a grant made on January 27, 2022, which vests over four years, with one-fourth vesting on January 1, 2023 and the remainder vesting monthly over the following 36 months, and they expire on January 27, 2032. Following the corrected transaction, the officer beneficially owns 104 derivative securities (remaining options) directly.
Globus Medical Senior Vice President and CFO Kyle Kline reported exercising stock options and selling the underlying shares. On January 8, 2026, he exercised 3,594 stock options for Class A common stock at an exercise price of $51.87 per share, receiving 3,594 shares. That same day, he sold 3,594 Class A common shares at a price of $101.10 per share under transaction code "S." After these transactions, he reported 0 shares of Class A common stock directly owned and 3,906 stock options remaining. The sale was carried out under a Rule 10b5-1 trading plan dated August 25, 2025, and the options exercised were part of a grant from March 14, 2024 that vests over four years.
Globus Medical director reports preset stock sale
Globus Medical director Leslie V. Norwalk reported selling 2,000 shares of the company’s Class A common stock on January 8, 2026 at a price of $101.10 per share. After this transaction, Norwalk beneficially owned 10,419 Class A shares, all held directly. The filing notes that the sale was made under a Rule 10b5-1 trading plan that was put in place on September 12, 2025, indicating the trades were pre-arranged rather than decided at the time of sale.
GMED insider plans a new stock sale under Rule 144. A person identified in the filing plans to sell 3,594 shares of common stock through Raymond James & Associates on the NYSE, with an indicated aggregate market value of 363,167.00. These shares were acquired from the issuer on 01/08/2026 through a cashless option exercise on the same date. The filing notes that 133,839,166 shares of common stock were outstanding. Over the prior three months, Kyle Kline sold 18,542 common shares on 12/01/2025, generating gross proceeds of 1,667,846.00. The signer represents that they are not aware of undisclosed material adverse information about the issuer.
GMED insider plans a small stock sale under Rule 144. A holder, identified as Leslie Norwalk, has filed to sell up to 2,000 shares of GMED common stock on the NYSE through Raymond James & Associates, with an indicated aggregate market value of $202,000. GMED had 133,839,166 common shares outstanding at the time listed.
The shares to be sold come from 10,000 common shares acquired on 09/01/2023 through RSU vesting from the issuer. Over the prior three months, the same seller disposed of 4,000 common shares on 12/12/2025 for gross proceeds of $355,188.